Studying the immune response of COVID-19 patients in the ICU
- Funded by The Ottawa Hospital Foundation
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AKnown Financial Commitments (USD)
$0Funder
The Ottawa Hospital FoundationPrincipal Investigator
Dr. Shirley MeiResearch Location
CanadaLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnosticsResearch Subcategory
ImmunitySpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
Why do some people get severely ill and die of COVID-19, while others experience only mild symptoms? Part of the answer may lie in how an individual's immune system reacts (and sometimes over-reacts) to the COVID-19 virus. Dr. Shirley Mei and her intensive care research colleagues will study this in critically ill COVID-19 patients using the world's most advanced "single-cell proteomics" technology. This technology, called CyTOF, will allow the researchers to study up to 60 different biological factors all at the same time from one single cell. The researchers will create a multi-dimensional map of the immune response to COVID-19, showing how it changes over time and how it sometimes goes out of control. The data will be shared with clinicians and researchers around the world, in order to improve treatment of COVID-19 and save lives.